Xenetic Biosciences and Santersus AG Announce Share Exchange Agreement

Xenetic Biosciences, Inc. and Santersus AG have announced a definitive share exchange agreement to create a Nasdaq-listed company focused on neutrophil extracellular traps (NETs) therapeutics. The combined entity will leverage Santersus' NucleoCapture® technology to physically remove NETs and Xenetic's DNase technology to degrade NETs in tissue.

The joint pipeline features four first-in-class programs, including pivotal-stage initiatives in sepsis and systemic lupus erythematosus, both with FDA Breakthrough Device Designation. The merger aims to advance the development of NET-targeting treatments across multiple medical fields.

The transaction, subject to stockholder approval, will result in the creation of Santersus Bio, Inc. With James Ladtkow expected as CEO, the merger positions the combined company as a leader in the emerging NET-targeting therapeutic field.